Clinical Trials
18 trialsNCT02522715 2026-02-24
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Active not recruiting
NCT03113500 2025-11-14
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05032183 2025-08-11
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03742258 2025-06-18
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
Phase 1 Completed
NCT02420717 2025-06-08
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00390793 2025-02-17
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03488225 2024-07-16
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02199184 2024-06-11
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02561273 2023-12-13
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
University of Nebraska
Phase 1/2 Completed
NCT03279250 2022-08-10
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03023046 2022-07-13
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Completed
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT02849990 2022-01-13
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
University of Washington
Phase 2 Completed
NCT01503229 2021-05-14
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Washington
Phase 2 Completed
NCT02844582 2021-01-25
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of California, Davis
Phase 2 Terminated
NCT02541565 2020-10-14
Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma
University of Washington
Phase 1 Completed
NCT03827473 2020-06-25
ACADEMIC
University of Utah
Phase 2 Terminated